Cagrilintide vs Pramlintide

Both mimic amylin, a pancreatic hormone co-released with insulin. Pramlintide is approved as a mealtime adjunct in diabetes; cagrilintide is a long-acting analogue developed for weekly dosing and combination with semaglutide.

HPLC tested · JanoshikJanoshik CertificatesNationwide DeliveryResearch Only

🧪

Cagrilintide

A long-acting amylin analogue, studied alone and in a fixed combination with semaglutide (CagriSema).

BEST STUDIED FOR

Incretin & metabolic

Read the cited profile →

🧪

Pramlintide

A synthetic analogue of the pancreatic hormone amylin, the first approved amylinomimetic.

BEST STUDIED FOR

Incretin & metabolic

Read the cited profile →

SIDE BY SIDE

	Cagrilintide	Pramlintide
The key difference	Long-acting acylated amylin analogue	Short-acting amylin analogue, approved
Class	Incretin & metabolic	Incretin & metabolic
Mechanism	Amylin is a pancreatic hormone co-secreted with insulin that induces satiety and slows gastric emptying.	Amylin is co-secreted with insulin; it lowers post-meal glucose by suppressing glucagon, slowing gastric emptying and reducing food intake.
Status	Phase 2 monotherapy data (2021) and phase 3 combination trials with semaglutide (REDEFINE, 2025–2026). Not yet approved.	Approved (2005, US) as an adjunct to mealtime insulin in type 1 and type 2 diabetes. The scientific ancestor of cagrilintide.
Reported safety signals	Trials report the gastrointestinal profile expected of the incretin/amylin class; the phase 1b study characterised tolerability of the combination.	Hypoglycaemia risk when combined with insulin is the key labelled concern; a randomised study found it could provoke migraine-like attacks in migraine patients.
A key study	A phase 2 dose-finding trial measured cagrilintide’s dose–response on body weight, safety and tolerability. (Lancet 2021, PMID 34798060)	Reviews pramlintide as the first amylinomimetic, approved in 2005 as an insulin adjunct. (Am J Health Syst Pharm 2005, PMID 16278328)

WHEN TO RESEARCH WHICH

Pramlintide is the clinical reference; cagrilintide is the investigational long-acting successor. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.

REFERENCES (PUBMED)

[Cagrilintide] Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial — Lancet 2021. PMID 34798060
[Cagrilintide] Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity — N Engl J Med 2025. PMID 40544433
[Cagrilintide] Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes — N Engl J Med 2025. PMID 40544432
[Pramlintide] Pramlintide acetate — Am J Health Syst Pharm 2005. PMID 16278328
[Pramlintide] Pramlintide in the treatment of type 1 and type 2 diabetes mellitus — Clin Ther 2005. PMID 16330288
[Pramlintide] Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients — Ann Neurol 2021. PMID 33772845

FREQUENTLY ASKED

What is the difference between Cagrilintide and Pramlintide?

What is the regulatory status of Cagrilintide and Pramlintide?

Cagrilintide: Phase 2 monotherapy data (2021) and phase 3 combination trials with semaglutide (REDEFINE, 2025–2026). Not yet approved. Pramlintide: Approved (2005, US) as an adjunct to mealtime insulin in type 1 and type 2 diabetes. The scientific ancestor of cagrilintide.

What safety signals have been reported?

Cagrilintide: Trials report the gastrointestinal profile expected of the incretin/amylin class; the phase 1b study characterised tolerability of the combination. Pramlintide: Hypoglycaemia risk when combined with insulin is the key labelled concern; a randomised study found it could provoke migraine-like attacks in migraine patients.

Which studies is this comparison based on?

For Cagrilintide: “Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial” (PMID 34798060); “Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity” (PMID 40544433); “Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes” (PMID 40544432). For Pramlintide: “Pramlintide acetate” (PMID 16278328); “Pramlintide in the treatment of type 1 and type 2 diabetes mellitus” (PMID 16330288); “Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients” (PMID 33772845).